These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37146611)

  • 1. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines.
    Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; West AP; Bjorkman PJ
    Cell; 2023 May; 186(11):2380-2391.e9. PubMed ID: 37146611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESCRT recruitment to mRNA-encoded SARS-CoV-2 spike induces virus-like particles and enhanced antibody responses.
    Hoffmann MAG; Yang Z; Huey-Tubman KE; Cohen AA; Gnanapragasam PNP; Nakatomi LM; Storm KN; Moon WJ; Lin PJC; Bjorkman PJ
    bioRxiv; 2022 Dec; ():. PubMed ID: 36597535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
    Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
    Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
    J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Qu L; Yi Z; Shen Y; Lin L; Chen F; Xu Y; Wu Z; Tang H; Zhang X; Tian F; Wang C; Xiao X; Dong X; Guo L; Lu S; Yang C; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Yisimayi A; Liu S; Huang W; Cao Y; Wang Y; Zhou Z; Peng X; Wang J; Xie XS; Wei W
    Cell; 2022 May; 185(10):1728-1744.e16. PubMed ID: 35460644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species.
    Peng L; Fang Z; Renauer PA; McNamara A; Park JJ; Lin Q; Zhou X; Dong MB; Zhu B; Zhao H; Wilen CB; Chen S
    Cell Rep; 2022 Aug; 40(5):111160. PubMed ID: 35921835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses.
    Sievers BL; Chakraborty S; Xue Y; Gelbart T; Gonzalez JC; Cassidy AG; Golan Y; Prahl M; Gaw SL; Arunachalam PS; Blish CA; Boyd SD; Davis MM; Jagannathan P; Nadeau KC; Pulendran B; Singh U; Scheuermann RH; Frieman MB; Vashee S; Wang TT; Tan GS
    Sci Transl Med; 2022 Mar; 14(634):eabn7842. PubMed ID: 35025672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.
    Ying B; Whitener B; VanBlargan LA; Hassan AO; Shrihari S; Liang CY; Karl CE; Mackin S; Chen RE; Kafai NM; Wilks SH; Smith DJ; Carreño JM; Singh G; Krammer F; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    Sci Transl Med; 2022 Feb; 14(630):eabm3302. PubMed ID: 34846168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
    Wu Y; Zhang H; Meng L; Li F; Yu C
    Front Immunol; 2022; 13():906457. PubMed ID: 35663946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.
    Ying B; Scheaffer SM; Whitener B; Liang CY; Dmytrenko O; Mackin S; Wu K; Lee D; Avena LE; Chong Z; Case JB; Ma L; Kim TTM; Sein CE; Woods A; Berrueta DM; Chang GY; Stewart-Jones G; Renzi I; Lai YT; Malinowski A; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    Cell; 2022 Apr; 185(9):1572-1587.e11. PubMed ID: 35452622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
    Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
    N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.
    Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I
    Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients.
    Tolan NV; Sherman AC; Zhou G; Nabel KG; Desjardins M; Melanson S; Kanjilal S; Moheed S; Kupelian J; Kaufman RM; Ryan ET; LaRocque RC; Branda JA; Dighe AS; Abraham J; Baden LR; Charles RC; Turbett SE
    Microbiol Spectr; 2022 Apr; 10(2):e0021122. PubMed ID: 35311584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
    Corleis B; Hoffmann D; Rauch S; Fricke C; Roth N; Gergen J; Kovacikova K; Schlottau K; Halwe NJ; Ulrich L; Schön J; Wernike K; Widera M; Ciesek S; Mueller SO; Mettenleiter TC; Maione D; Petsch B; Beer M; Dorhoi A
    Nat Commun; 2023 Feb; 14(1):816. PubMed ID: 36781853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.